• Covid-19 and cardiovascular and metabolic disease

Fried et al. The Variety of Cardiovascular Presentations of COVID-19. Circulation. 2020 Apr 3. doi: 10.1161/CIRCULATIONAHA.120.047164. https://www.ahajournals.org/doi/pdf/10.1161/CIRCULATIONAHA.120.047164

 Guo J et al. Coronavirus Disease 2019 (COVID-19) and Cardiovascular Disease: A Viewpoint on the Potential Influence of Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers on Onset and Severity of Severe Acute Respiratory Syndrome Coronavirus 2 Infection. J Am Heart Assoc. 2020 Apr 7;9(7):e016219. doi: 10.1161/JAHA.120.016219. Epub 2020 Apr 1. https://www.ncbi.nlm.nih.gov/pubmed/32233755

Hill et al. Commentary: COVID-19 in Patients with Diabetes. Metabolism. 2020 Mar 24:154217. doi: 10.1016/j.metabol.2020.154217.  https://www.ncbi.nlm.nih.gov/pubmed/32220611

Gup et al. Cardiovascular Implications of Fatal Outcomes of Patients With Coronavirus Disease 2019 (COVID-19). JAMA Cardiol. 2020 Mar 27. doi: 10.1001/jamacardio.2020.1017. https://www.ncbi.nlm.nih.gov/pubmed/32219356

Madjid et al. Potential Effects of Coronaviruses on the Cardiovascular System. A Review. https://jamanetwork.com/journals/jamacardiology/fullarticle/2763846

Huang et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020 Feb 15;395(10223):497-506. doi: 10.1016/S0140-6736(20)30183-5. Epub 2020 Jan 24. https://www.ncbi.nlm.nih.gov/pubmed/31986264

Elkind et al. Role of the American Heart Association in the Global COVID-19 Pandemic. Circulation. 2020 Mar 17. doi: 10.1161/CIRCULATIONAHA.120.046749. https://www.ncbi.nlm.nih.gov/pubmed/32181680

Zhou et al. Diabetes patients with COVID-19 need better blood glucose management in Wuhan, China. Metabolism. 2020 Mar 24;107:154216. doi: 10.1016/j.metabol.2020.154216.  https://www.ncbi.nlm.nih.gov/pubmed/32220612

South et al. COVID-19, ACE2 and the Cardiovascular Consequences. Am J Physiol Heart Circ Physiol. 2020 Mar 31. doi: 10.1152/ajpheart.00217.2020. https://www.ncbi.nlm.nih.gov/pubmed/32228252

 

• Covid-19 and kidney disease

Fu et al. COVID-19 Infection in a Patient with End-Stage Kidney Disease. Nephron. 2020 Mar 27:1-3. doi: 10.1159/000507261. https://www.ncbi.nlm.nih.gov/pubmed/32222703

Choi et al. Renal replacement therapy is independently associated with a lower risk of death in patients with severe acute kidney injury treated with targeted temperature management after out-of-hospital cardiac arrest. Crit Care. 2020 Mar 23;24(1):115. doi: 10.1186/s13054-020-2822-x.https://www.ncbi.nlm.nih.gov/pubmed/32204725

Perico et al. Should COVID-19 Concern Nephrologists? Why and to What Extent? The Emerging Impasse of Angiotensin Blockade. Nephron. 2020 Mar 23:1-9. doi: 10.1159/000507305. https://www.ncbi.nlm.nih.gov/pubmed/32203970

 Zhan et al. The potential risk of kidney vulnerable to novel coronavirus 2019 infection. Am J Physiol Renal Physiol. 2020 Mar 30. doi: 10.1152/ajprenal.00085.2020. https://www.ncbi.nlm.nih.gov/pubmed/32223555

Cheng et al. Kidney disease is associated with in-hospital death of patients with COVID-19. Kidney Int. 2020 Mar 20. pii: S0085-2538(20)30255-6. doi: 10.1016/j.kint.2020.03.005. https://www.ncbi.nlm.nih.gov/pubmed/32247631

Henry et al. Chronic kidney disease is associated with severe coronavirus disease 2019 (COVID-19) infection. Int Urol Nephrol. 2020 Mar 28. doi: 10.1007/s11255-020-02451-9. https://www.ncbi.nlm.nih.gov/pubmed/32222883